The treatment of arterial hypertension with a new alpha-blocker, indoramin

Abstract

Thirty patients with moderate essential hypertension were treated with indoramin, a new alpha-adrenoceptor blocking agent. After 2 weeks on placebo for stabilization of the blood pressure and screening of cases with stable hypertension, treatment was started with 20 mg. t.i.d. Drug was titrated in each patient and the effective dosage was found to be between 150 and 300 mg. per day. Twenty-five patients were followed for 12 weeks, 4 for 11 weeks and 1 for 9 weeks. This last one was the only patient who failed to respond to treatment. The results were considered excellent or good in 25 of the 30 patients. No significant side-effects were recorded. There were no abnormal laboratory findings. Tolerance to standardised excercise appeared to be increased.